Article
Endocrinology & Metabolism
J. Moreno-Fernandez, P. Beato-Vibora, P. Olvera, J. A. Garcia-Seco, F. Gallego-Gamero, M. T. Herrera, J. R. Munoz-Rodriguez
Summary: This study analyzed the real-life outcomes of T1DM patients using two sensor-augmented pumps with predictive low glucose suspend function and found that both pumps showed similar glycemic control in a real-world scenario.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2021)
Article
Endocrinology & Metabolism
Keiji Sugai, Junpei Shikuma, Satoshi Hiroike, Hironori Abe, Ryo Suzuki
Summary: Using a sensor-augmented pump (SAP) can effectively assist adults with needle phobia and diabetes requiring insulin therapy in self-management, improving glycemic control and treatment satisfaction.
JOURNAL OF DIABETES INVESTIGATION
(2023)
Article
Endocrinology & Metabolism
Katrien Benhalima, Falco van Nes, Annouschka Laenen, Pieter Gillard, Chantal Mathieu
Summary: This study aimed to compare the frequency of ketonaemia in pregnant women with type 1 diabetes treated with a sensor-augmented pump in predictive low glucose suspend (PLGS) mode versus low glucose suspend (LGS) mode. The results showed that despite longer periods of suspended insulin delivery, pregnant women using an SAP in PLGS mode did not have a higher risk of developing ketonaemia compared to those in LGS mode, while also showing similar time in range and less time in hypoglycemia.
Article
Endocrinology & Metabolism
David Herzig, David Studer, Christos T. Nakas, Christina Kuenzli, Thomas P. Stauffer, Roman Hovorka, Lia Bally
Summary: This study retrospectively assessed the effects of fully automated closed-loop insulin delivery using faster (FA) versus standard insulin aspart (IAsp) in adults with type 2 diabetes. The results showed that FA had higher 10-hour exposure compared to IAsp, but this did not significantly impact endogenous insulin secretion or other gluco-regulatory hormones. Further research is needed to explore the metabolic and endocrine effects of novel insulins with accelerated pharmacokinetic properties.
DIABETES OBESITY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Eric Renard
Summary: Automated insulin delivery systems, known as closed-loop systems or artificial pancreas, use blood glucose levels to drive insulin supply, resulting in improved blood sugar control and reduced risk of hypoglycemia for type 1 diabetes patients. Although current AID systems require meal and exercise announcements for insulin adjustment, they represent a significant milestone in diabetes treatment and pave the way for future fully automated and more physiological closed-loop systems.
ACTA DIABETOLOGICA
(2023)
Article
Public, Environmental & Occupational Health
Qiong Luo, Li Zhou, Naitong Zhou, Ming Hu
Summary: This study evaluated the long-term cost effectiveness of insulin degludec/insulin aspart (IDegAsp) vs. biphasic insulin aspart 30 (BIAsp 30) for the treatment of Chinese patients with inadequately managed type 2 diabetes mellitus (T2DM). The results showed that IDegAsp was associated with higher life years and quality-adjusted life years compared to BIAsp 30 over a 30-year time horizon. Additionally, the total costs were slightly higher with IDegAsp therapy. Therefore, IDegAsp was considered a cost-effective treatment option for people with inadequate glycemic management on basal insulin in China.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Endocrinology & Metabolism
Maria Elena Lunati, Paola Silvia Morpurgo, Antonio Rossi, Alessandra Gandolfi, Irene Cogliati, Andrea Mario Bolla, Laura Plebani, Luciana Vallone, Laura Montefusco, Ida Pastore, Vincenzo Cimino, Sabrina Argenti, Graziella Volpi, Gian Vincenzo Zuccotti, Paolo Fiorina
Summary: This study found that hybrid closed-loop systems can improve glucose control and reduce the risk of hypoglycemia in patients with type 1 diabetes, while positively affecting the acceptance of diabetes technologies.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Pilar Beato-Vibora, Fabiola Gallego-Gamero, Ana Ambrojo-Lopez
Summary: This study evaluated the real-world benefits of different treatment modalities for T1D. Results showed that HCL offers the maximum benefit in terms of maintaining time in range and protecting against hypoglycemia.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
(2021)
Article
Endocrinology & Metabolism
Alessandro Bisio, Sue A. Brown, Ryan McFadden, Michael Pajewski, Pearl L. Yu, Mark DeBoer, Melissa J. Schoelwer, Heather G. Bonner, Christian A. Wakeman, Daniel R. Chernavvsky, Linda Gonder-Frederick
Summary: The study found that the use of the automated insulin delivery system Control-IQ had a positive impact on glycemic outcomes in young children with T1D, as well as improvements in parents' sleep and diabetes-specific quality of life.
PEDIATRIC DIABETES
(2021)
Article
Medicine, General & Internal
Mark A. Sperling, Lori M. Laffel
Summary: A 12.5-year-old pubertal girl is referred to a tertiary medical center for management of new-onset diabetes mellitus. The initial evaluation reveals glucosuria but no ketonuria. She has no family history of type 1 diabetes mellitus and her physical examination is normal except for Tanner stage 3 breast and pubic hair development.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Endocrinology & Metabolism
C. Thivolet, M. Gaudilliere, S. Villar Fimbel, N. Bendelac, B. Mestre, N. Protsenko, S. Brunot, M. Nicolino
Summary: The study showed that initiation of insulin pump therapy for outpatients is safe and telehealth monitoring after outpatient initiation can help improve glucose control. Hybrid Closed Loop systems are compatible with outpatient pump initiation and provide the largest improvements in glucose control.
ACTA DIABETOLOGICA
(2022)
Article
Endocrinology & Metabolism
Quoc Dat Do, Aneta Haskova, Lucie Radovnicka, Judita Konecna, Eva Horova, Christopher G. Parkin, George Grunberger, Martin Prazny, Jan Soupal
Summary: This study compared open-source AndroidAPS (AAPS) and commercially available Control-IQ (CIQ) automated insulin delivery (AID) systems. The results showed that CIQ and AAPS were comparable in achieving time in range (TIR), but CIQ had a significantly lower rate of hypoglycemia compared to AAPS.
DIABETES OBESITY & METABOLISM
(2023)
Article
Nutrition & Dietetics
Kirthi Menon, Barbora de Courten, Dianna J. Magliano, Zanfina Ademi, Danny Liew, Ella Zomer
Summary: This study assessed the cost-effectiveness of daily 1g carnosine supplementation in addition to standard care for the management of type 2 diabetes and compared it to standard care alone. The results showed that supplemental dietary carnosine may be a cost-effective treatment option for people with type 2 diabetes in Australia.
Article
Endocrinology & Metabolism
Hitomi Imafuku, Kenji Tanimura, Naohisa Masuko, Masako Tomimoto, Yutoku Shi, Akiko Uchida, Masashi Deguchi, Kazumichi Fujioka, Akane Yamamoto, Kei Yoshino, Yushi Hirota, Wataru Ogawa, Yoshito Terai
Summary: This retrospective cohort study compared the efficacy of sensor-augmented pump (SAP) with continuous subcutaneous insulin infusion plus self-monitoring of blood glucose (continuous subcutaneous insulin infusion [CSII]/SMBG) in pregnant women with type 1 diabetes mellitus. The study found that SAP therapy was more effective in preventing large for gestational age newborns and had lower levels of glycoalbumin, hemoglobin A1c, and standard deviation score of birthweights compared to CSII/SMBG therapy. No significant differences were observed in other obstetric and neonatal outcomes between the two groups.
JOURNAL OF DIABETES INVESTIGATION
(2023)
Review
Medicine, General & Internal
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R. Webb, Melanie J. Davies
Summary: Type 2 diabetes accounts for nearly 90% of global diabetes cases, with an increasing number of affected individuals, particularly among young people. Early detection and proactive management are crucial for preventing complications and reducing mortality. Technology and precision medicine offer potential improvements to treatment outcomes but face significant barriers.